KR102563191B1 - 비피도박테리움 애니멀리스 ssp. 락티스를 이용한 암 치료 조성물 및 방법 - Google Patents

비피도박테리움 애니멀리스 ssp. 락티스를 이용한 암 치료 조성물 및 방법

Info

Publication number
KR102563191B1
KR102563191B1 KR1020207003258A KR20207003258A KR102563191B1 KR 102563191 B1 KR102563191 B1 KR 102563191B1 KR 1020207003258 A KR1020207003258 A KR 1020207003258A KR 20207003258 A KR20207003258 A KR 20207003258A KR 102563191 B1 KR102563191 B1 KR 102563191B1
Authority
KR
South Korea
Prior art keywords
delete delete
cancer
lactis
carcinoma
animalis ssp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207003258A
Other languages
English (en)
Korean (ko)
Other versions
KR20200024911A (ko
Inventor
피터 샌디
재클린 팝코프
마리아 시조바
브라이언 굿맨
험프리 가드너
홀리 포니크테라
행크 우
윌리암 카프리
아누프리야 두타
Original Assignee
에벨로 바이오사이언시즈, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63036353&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102563191(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 에벨로 바이오사이언시즈, 인크. filed Critical 에벨로 바이오사이언시즈, 인크.
Publication of KR20200024911A publication Critical patent/KR20200024911A/ko
Application granted granted Critical
Publication of KR102563191B1 publication Critical patent/KR102563191B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Developmental Biology & Embryology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020207003258A 2017-07-05 2018-07-05 비피도박테리움 애니멀리스 ssp. 락티스를 이용한 암 치료 조성물 및 방법 Active KR102563191B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762528669P 2017-07-05 2017-07-05
US62/528,669 2017-07-05
PCT/US2018/040841 WO2019010255A1 (en) 2017-07-05 2018-07-05 COMPOSITIONS AND METHODS FOR TREATING CANCER USING BIFIDOBACTERIUM ANIMALIS SSP. LACTIS

Publications (2)

Publication Number Publication Date
KR20200024911A KR20200024911A (ko) 2020-03-09
KR102563191B1 true KR102563191B1 (ko) 2023-08-02

Family

ID=63036353

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207003258A Active KR102563191B1 (ko) 2017-07-05 2018-07-05 비피도박테리움 애니멀리스 ssp. 락티스를 이용한 암 치료 조성물 및 방법

Country Status (12)

Country Link
US (3) US10792314B2 (cg-RX-API-DMAC7.html)
EP (1) EP3648780A1 (cg-RX-API-DMAC7.html)
JP (1) JP7254786B2 (cg-RX-API-DMAC7.html)
KR (1) KR102563191B1 (cg-RX-API-DMAC7.html)
CN (1) CN111356464A (cg-RX-API-DMAC7.html)
AR (1) AR112328A1 (cg-RX-API-DMAC7.html)
AU (1) AU2018298087A1 (cg-RX-API-DMAC7.html)
BR (1) BR112019028301A2 (cg-RX-API-DMAC7.html)
CA (1) CA3068757A1 (cg-RX-API-DMAC7.html)
MA (1) MA51770A (cg-RX-API-DMAC7.html)
TW (1) TW201906620A (cg-RX-API-DMAC7.html)
WO (1) WO2019010255A1 (cg-RX-API-DMAC7.html)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
HK1253064A1 (zh) * 2015-06-01 2019-06-06 The University Of Chicago 通过操纵共生微生物菌群对癌症的治疗
MA41010B1 (fr) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
JP7217700B2 (ja) 2016-09-13 2023-02-03 アラーガン、インコーポレイテッド 安定化非タンパク質クロストリジウム毒素組成物
MA48940A (fr) 2017-05-22 2020-04-08 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
MA41708A (fr) 2017-05-24 2020-04-08 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
TWI767013B (zh) 2017-06-14 2022-06-11 英商4D製藥研究有限公司 包含細菌品系之組成物
PL3638271T3 (pl) 2017-06-14 2021-03-22 4D Pharma Research Limited Kompozycje zawierające szczepy bakteryjne
JP2020523326A (ja) 2017-06-14 2020-08-06 フォーディー ファーマ リサーチ リミテッド4D Pharma Research Limited 細菌株を含む組成物
KR102563191B1 (ko) 2017-07-05 2023-08-02 에벨로 바이오사이언시즈, 인크. 비피도박테리움 애니멀리스 ssp. 락티스를 이용한 암 치료 조성물 및 방법
WO2019180051A1 (en) 2018-03-19 2019-09-26 4D Pharma Research Limited Compositions comprising bacterial strains
CN112566648A (zh) 2018-07-16 2021-03-26 4D制药研究有限公司 包含细菌菌株的组合物
AU2019396657A1 (en) 2018-12-12 2021-07-08 4D Pharma Research Limited Compositions comprising Parabacteroides bacterial strains for treating cancer
JP2022537684A (ja) * 2019-06-11 2022-08-29 エヴェロ バイオサイエンシズ,インコーポレーテッド 分泌された微生物細胞外小胞
WO2021022110A1 (en) 2019-08-01 2021-02-04 Evelo Biosciences, Inc. Inducing immune effects using bacteria of the genus bifidobacterium
KR102357904B1 (ko) * 2019-10-29 2022-02-04 경희대학교 산학협력단 항암용 금 나노입자
CN112618577B (zh) * 2020-12-15 2023-07-25 深圳君拓生物科技有限公司 动物双歧杆菌在提高肿瘤免疫治疗应答中的作用
WO2022164870A1 (en) * 2021-01-26 2022-08-04 Cb Therapeutics, Inc. Recombinant polyprenol diphosphate synthases
TW202304415A (zh) * 2021-04-08 2023-02-01 美商艾弗洛生物科技股份有限公司 含有細菌的藥物製劑
CN113368259B (zh) * 2021-06-22 2022-07-22 海南大学 一种基于修饰细菌加载纳米药物的方法及其复合物和在治疗结肠癌中的应用
US20230096810A1 (en) * 2021-09-24 2023-03-30 Johnson & Johnson Consumer Inc. Dosage forms for the delivery of a probiotic
CN114028432A (zh) * 2021-11-05 2022-02-11 上海市第十人民医院 双歧杆菌提升铂类化疗药物敏感性的药物新用途
CN115363094A (zh) * 2021-11-30 2022-11-22 内蒙古伊利实业集团股份有限公司 乳双歧杆菌bl-99在预防和/或改善胃炎中的应用
CN114480229B (zh) * 2022-04-15 2022-08-09 微康益生菌(苏州)股份有限公司 一种动物双歧杆菌乳亚种菌株wkb148及其产品与应用
CN115216423B (zh) * 2022-06-15 2023-04-25 南昌大学 一种动物双歧杆菌sf及其在医药和食品中的应用
WO2025071560A1 (en) * 2023-09-28 2025-04-03 Rutgers, The State University Of New Jersey Methods of diagnosing b cell malignancies, detecting b cell malignancy relapse, and treating thereof
CN117417866B (zh) * 2023-10-27 2026-02-27 江南大学 一种产胆盐水解酶的动物双歧杆菌及其在新生儿黄疸中的应用
CN117327632B (zh) * 2023-12-01 2024-02-13 四川厌氧生物科技有限责任公司 一种动物双歧杆菌及其应用
CN121046519B (zh) * 2025-11-05 2026-03-20 中国食品发酵工业研究院有限公司 动物双歧杆菌乳亚种bl-99的活菌定量检测方法及其引物、探针、试剂盒与应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104224851A (zh) * 2014-08-15 2014-12-24 任发政 动物双歧杆菌乳酸亚种CGMCC No.9273的应用
JP2016517425A (ja) * 2013-03-14 2016-06-16 セラバイオーム,エルエルシー プロバイオティクス生物及び/又は治療剤の標的化胃腸管デリバリー
WO2016196605A1 (en) * 2015-06-01 2016-12-08 The University Of Chicago Treatment of cancer by manipulation of commensal microflora
JP2017514857A (ja) * 2014-05-05 2017-06-08 ジョヴァンニ・モーニャGiovanni MOGNA 腫瘍、後天性免疫不全症候群および白血病の二重免疫バイオスティミュレーションによる処置における使用のための治療剤

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ID29150A (id) 1999-01-15 2001-08-02 Entpr Ireland Cs Penggunaan lactobacillus salivarius
US20030092163A1 (en) 2001-07-26 2003-05-15 Collins John Kevin Probiotic bifidobacterium strains
GB0307026D0 (en) 2003-03-27 2003-04-30 Rowett Res Inst Bacterial supplement
EP1481681A1 (en) 2003-05-30 2004-12-01 Claudio De Simone Lactic acid bacteria combination and compositions thereof
JP4683881B2 (ja) 2003-08-27 2011-05-18 有限会社アーク技研 抗腫瘍活性剤
GB0323039D0 (en) 2003-10-01 2003-11-05 Danisco Method
EP1714660A1 (en) 2005-04-21 2006-10-25 N.V. Nutricia Uronic acid and probiotics
EP2046352A4 (en) 2006-06-06 2012-03-21 Univ Mcgill Fermented milk product and use thereof
US20080069861A1 (en) 2006-09-19 2008-03-20 National Starch And Chemical Investment Holding Corporation Probiotic/Non-Probiotic Combinations
PL1920781T3 (pl) 2006-11-10 2015-06-30 Glycotope Gmbh Kompozycje zawierające core-1-dodatnie mikroorganizmy i ich zastosowanie w leczeniu lub profilaktyce nowotworów
NZ580006A (en) 2007-03-28 2012-03-30 Alimentary Health Ltd Probiotic bifidobacterium strain 41387
US8557233B2 (en) 2007-03-28 2013-10-15 Alimentary Heath Limited Probiotic bifidobacterium strains
EP1997907A1 (en) 2007-06-01 2008-12-03 Friesland Brands B.V. Bifidobacteria
US20110027348A1 (en) 2007-08-27 2011-02-03 Janos Feher Composition and method inhibiting inflammation
EP2203551B1 (en) 2007-10-20 2013-08-21 Université de Liège Bifidobacterial species
US8586029B2 (en) 2008-06-04 2013-11-19 Trustees Of Dartmouth College Prevention or treatment of immune-relevant disease by modification of microfloral populations
PL2498789T3 (pl) 2009-11-11 2017-01-31 Alimentary Health Limited Probiotyczny szczep bifidobacterium
WO2012142605A1 (en) 2011-04-15 2012-10-18 Samaritan Health Services Rapid recolonization deployment agent
EP3033091B1 (en) 2013-08-16 2022-09-07 Versitech Limited Probiotic composition and use thereof in the prevention and treatment of hepatocellular carcinoma
US10203329B2 (en) 2013-09-12 2019-02-12 The Johns Hopkins University Biofilm formation to define risk for colon cancer
EP2876167A1 (en) 2013-11-21 2015-05-27 Institut Gustave Roussy Microbiota composition, as a marker of responsiveness to chemotherapy, and use of microbial modulators (pre-,pro- or synbiotics) for improving the efficacy of a cancer treatment
MA41020A (fr) 2014-11-25 2017-10-03 Evelo Biosciences Inc Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome
SG10201907660YA (en) 2015-01-23 2019-10-30 Univ Temple Use of short chain fatty acids in cancer prevention
EP3285777B1 (en) 2015-04-23 2021-06-09 Kaleido Biosciences, Inc. Glycan therapeutics and methods of treatment
SG11201708635QA (en) 2015-04-23 2017-11-29 Kaleido Biosciences Inc Microbiome regulators and related uses thereof
LT3360559T (lt) 2015-06-15 2019-12-27 4D Pharma Research Limited Kompozicijos, apimančios bakterijų kamienus
CN106110322A (zh) * 2016-07-29 2016-11-16 安徽瀚海博兴生物技术有限公司 一种药物组合物及其在制备治疗癌症药物中的应用
KR102563191B1 (ko) 2017-07-05 2023-08-02 에벨로 바이오사이언시즈, 인크. 비피도박테리움 애니멀리스 ssp. 락티스를 이용한 암 치료 조성물 및 방법

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016517425A (ja) * 2013-03-14 2016-06-16 セラバイオーム,エルエルシー プロバイオティクス生物及び/又は治療剤の標的化胃腸管デリバリー
JP2017514857A (ja) * 2014-05-05 2017-06-08 ジョヴァンニ・モーニャGiovanni MOGNA 腫瘍、後天性免疫不全症候群および白血病の二重免疫バイオスティミュレーションによる処置における使用のための治療剤
CN104224851A (zh) * 2014-08-15 2014-12-24 任发政 动物双歧杆菌乳酸亚种CGMCC No.9273的应用
WO2016196605A1 (en) * 2015-06-01 2016-12-08 The University Of Chicago Treatment of cancer by manipulation of commensal microflora

Also Published As

Publication number Publication date
AU2018298087A1 (en) 2020-01-23
TW201906620A (zh) 2019-02-16
US10576111B2 (en) 2020-03-03
AR112328A1 (es) 2019-10-16
US20190224253A1 (en) 2019-07-25
CA3068757A1 (en) 2019-01-10
JP7254786B2 (ja) 2023-04-10
KR20200024911A (ko) 2020-03-09
US20190192585A1 (en) 2019-06-27
MA51770A (fr) 2020-05-13
EP3648780A1 (en) 2020-05-13
US10792314B2 (en) 2020-10-06
BR112019028301A2 (pt) 2020-07-14
JP2020526581A (ja) 2020-08-31
CN111356464A (zh) 2020-06-30
US20210093680A1 (en) 2021-04-01
WO2019010255A1 (en) 2019-01-10

Similar Documents

Publication Publication Date Title
AU2021254635B2 (en) Compositions comprising bacterial strains
KR20200024911A (ko) 비피도박테리움 애니멀리스 ssp. 락티스를 이용한 암 치료 조성물 및 방법
AU2018250519B2 (en) Compositions and methods for improving lettuce production
CN100558896C (zh) 双岐杆菌的基因组
KR102530297B1 (ko) 미생물유전체를 조정함으로써 면역 체크포인트 차단 요법을 증강시키는 방법
AU2017380257B2 (en) Microbiota composition, as a marker of responsiveness to anti-PD1/PD-L1/PD-L2 antibodies and use of microbial modulators for improving the efficacy of an anti-PD1/PD-L1/PD-L2 ab-based treatment
AU2017234120B2 (en) Modulation of the gut microbiome to treat mental disorders or diseases of the central nervous system
AU2023251441A1 (en) RNA containing composition for treatment of tumor diseases
AU2020227049A1 (en) Fast diagnosis and personalized treatments for acne
AU2023214237A1 (en) Modified polynucleotides for the production of biologics and proteins associated with human disease
TW202321448A (zh) 利用重組環狀rna改善蛋白質轉譯的組合物及方法
AU2017289886A1 (en) Engineered parasites for delivering protein to the central nervous system (CNS)
KR102880582B1 (ko) 다중화 게놈 편집
CN107208149A (zh) 结直肠癌相关疾病的生物标志物
AU2016295122A1 (en) Genetic testing for predicting resistance of pseudomonas species against antimicrobial agents
AU2016295177A1 (en) Genetic testing for predicting resistance of serratia species against antimicrobial agents
KR20220004117A (ko) 증가된 저장 안정성을 갖는 프로바이오틱 균주
KR20190057790A (ko) Nattokinase 활성을 가지는 신규 고초균 및 이의 용도
KR101561591B1 (ko) 지질 분해효소 LipT를 생산하는 신규한 내냉성 슈도모나스 만델리 JR-1 균주 및 그 유전체의 염기서열
KR20220139525A (ko) 황산화능을 가지는 신규 에시디티오바실러스 속 균주 및 이를 이용한 이산화탄소의 포집방법
AU2020100851A4 (en) Method for controlling rotten eggs in hatcheries by utilizing phages
KR101569384B1 (ko) 지질 분해효소 LipT를 생산하는 신규한 내냉성 슈도모나스 만델리 JR-1 균주 및 그 유전체의 염기서열
KR101651015B1 (ko) 지질 분해효소 LipT를 생산하는 신규한 내냉성 슈도모나스 만델리 JR-1 균주 및 그 유전체의 염기서열
KR101597276B1 (ko) 지질 분해효소 LipT를 생산하는 신규한 내냉성 슈도모나스 만델리 JR-1 균주 및 그 유전체의 염기서열
AU2016299328A1 (en) Genetic testing for predicting resistance of stenotrophomonas species against antimicrobial agents

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20200204

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210705

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230216

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20230519

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20230731

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20230731

End annual number: 3

Start annual number: 1

PG1601 Publication of registration